SI. No.	Name of the company	Name of the bulk drug
26	M/s Lyka Labs	Rifampicin
27	M/s Lyka Labs Ltd .	Ethambutol
28	M/s Dolphin Labs Ltd.	Amoxycillin Trihydrate
29	M/s Astra- IDL Ltd.	Ibuprofen
30	M/s Ranbaxy Labs Ltd.	Rifampicin
31	M/s Themis Chemicals	Rifampicin
32	M/s Cipla Ltd.	Metronidazole
33	M/s Lyka Labs Ltd.	Amoxycillin Trihydrate
34	M/s Knoll Pharmaceutical	Ibuprofen
35	M/s Themis Chemicals	Ethambutol
36	M/s Lyka Labs	Fluocinolone Acetonide
37	M/s Dolphin Labs Ltd.	Metronidazole
38	M/s Tamil Nadu Dadha	Calcium Lactate
39	M/s Boehringer Mannheim (India) Ltd	. Euglucon Tabs
40	M/s U.S. Vitamins Ltd.	Doxycycline
41	M/s Dolphin Labs Ltd.	Sulphamethaxazole & Trimethoprim
42	M/s S.G. Pharmaceuticals (M/s Ambalal Sarabhai Enterprises Ltd.)	Oxyphenbutazone
43	M/s Ethico Drugs & Chemicals Mfg. Co. Ltd.	Rifampicin

Settlement Commission on DPEA cases

1823. SHRI UDAYPRATAP SINGH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) what are the details of DPEA liabilities which are due from the MNCs and the Indian companies;

(b) what are the names of the companies, names of the drugs and the amount involved;

(c) whether Government are intending to form a Settlement Commission for the same; and

(d) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI B.K. HANDIQUE): (a) and (b) The Drug Prices Liabilities Review Committee (DPLRC) issued notices in 72 cases involving 71 companies (one case merged with another) both to the MNCs and the Indian companies for representation/submissions from these companies against the liabilities communicated by the Department of Chemicals & Petrochemicals till the interim stay dated 30.6.1997 was granted by the Hon'ble Bombay High Court in Writ Petition No. 2368/1996 filed by Indian Drug Manufacturers' Association (IDMA) and Organisation of Pharmaceutical Producers of India (OPPI) restraining the Department and its committees etc. from issuing fresh notices to the drug companies calling for information required for determining liablilities. In totality, out of the 72 cases referred to DPLRC, the Committee submitted its report in respect of 47 cases. At present, there are 25 cases pending with DPLRC because of the stay granted by Hon'ble High Court where no quantification can be done till the vacation of the stay. In addition to these 25 cases, there may be a large number of cases in respect of other bulk drugs where the liability would be quantified after the above said stay is vacated. Presently, DPLRC has been kept under suspended animation with effect from 31st December, 2005 as no new cases could be taken by the Committee for quantification due to the stay given by the Hon'ble Bombay High Court. On the basis of the recommendations of the DPLRC, the Department computed liability in respect of 16 companies. After the issue of revised terms of reference of the Committee on 10.10.2002, DPLRC quantified the amount of liability in 30 cases (29 companies). A statement containing the names of the companies, drugs and the amount involved is attached as Statement-I.

(c) and (d) Considering the prevailing litigation in DPEA liability cases which pertain to the period with effect from 1.4.1979 to 25.8.1987, and the fact that most of the companies to whom demand notices have been sent, have moved various High Courts it seems worthwhile to settle these cases either through Settlement Commission or through any other Scheme. However, a decision in this regard has not yet been taken.

Statement-I

Names of Companies and Drugs and the amount of liability involved on the basis of recommendations of DPLRC

(A) Name of the companies, name of the drugs and the amount of liability computed by the Department on the basis of recommendations of the DPLRC prior to 10.10.2002 i.e. before revised terms of reference of the DPLRC

SI. No.	Name of the company	Name of the bulk drug	Amount of DPEA liability assessed by the Department on the basis of Reports of DPLRC . (Rs. in lakhs)
1.	M/s. Anil Starch Products Ltd.	Dextrose Anhydrous	34.53
2.	M/s. Franco Indian Pharma & M/s. Griffon Labs M/s .Parke Davis (I) Ltd.	Phenoxymethyl Penicillin formulations (Penivoral Tabs) Isokin Tab & Liquid	77.35
4.	M/s. Wallace Pharma Ltd.	Rifampicin	8.08
5.	M/s. Astra IDL Ltd.	Rifampicin	51.07
6.	M/s. Wyeth Lederle	Dexamethasone	277.39
7.	M/s. Biddle Sawyers Ltd.	Salbutamol Sulphate	440.79
8.	M/s. PCI Ltd.	Rifampicin	256.87
9.	M/s. PCI Ltd.	Amoxycillin Trihydrate	154.79
10.	M/s. Bayer (India) Ltd.	Chloroquin Phosphate	275.81
11.	M/s. PCI Ltd.	Gentamycin Sulphate	398.20
12.	M/s. Yash Pharma Labs	Ethambutol	59.78
13.	M/s. PCI Ltd.	Ethambutol	208.12
14.	M/s. PCI Ltd.	Ampicillin Trihydrate	374.53
15.	M/s. Pharmed Ltd.	Rifampicin	96.31
16.	M/s. Alembic Chemical Works	Rifampicin	112.92

(B) Name of the company, drugs and amount of liability quantified by the DPLRC.

SI. No.	Name of the Company	Name of the bulk drug	Amount of liability quantified by the DPLRC (Rs. in lakhs)
1.	M/s. Merind Ltd.	Dexamethasone	677281
2.	M/s. Biochem Pharma Industries	Refampicin	99.76
3.	M/s. Lupin Laboratories	Rifampicin	1065.09
4.	M/s. Unique Pharmaceuticals	Oxyphenabutazone	591.05
5.	M/s. Ambalal Sarabhai Enterprises	Amoxycillin Trihydrate	84.13
6.	M/s. Gufic Ltd.	Amoxycillin Trihydrate	73.86
7.	M/s. Lyka Labs.	Ampicillin Trihydrate	70.37
8.	M/s. Unique Pharma Labs Ltd.	Metronidazole	461.47
9.	M/s. Ranbaxy Laboratories Ltd.	Ampicillin Trihydrate	416.84
10.	M/s. Lyka Cabs	Rifampicin	148.38
11.	M/s. Lyka Labs Ltd.	Ethambutol	38.50
12.	M/s. Dolphin Labs Ltd.	Amoxycillin Trihydrate	51.53
13.	M/s. Astra IDL Ltd.	Ibuprofen	174.86
14.	-M/s. Ranbaxy Labs Ltd.	Rifampicin	223.00
15.	M/s. Themis Chemicals	Refampicin	126.07
16.	M/s. Cipla Ltd.	Metronidazole	22.81
17.	M/s. Lyka Labs Ltd.	Amoxycillin Trihydrate	13.95
18.	M/s. Knoll Pharmaceutical	Iburprofen	346.64/57.67@
19.	M/s. Themis Chemicals	Ethamubtol	200.00
20.	M/s. Lyka Labs	Fluocinolone Acetonide	1804.65/Nil@
21	M/s. Dolphin Labs Ltd.	Metronidazole	26.66
22.	M/s. Tamil Nadu Dadha	Clacium Lactate	130.34/ 120.90@
23.	M/s. Boehringer Mannheim (India) Ltd.	Euglucon Tabs	313.17
24.	M/s. U.S. Vitamins Ltd.	Doxycycline	132.62/125.19@
25.	M/s. Dolphin Labs Ltd.	Sulphamethaxazole & Trimethoprim	54.20/11.45@

Sl. No.	Name of the Company	Name of the bulk drug	Amount of liability quantified by the DPLRC (Rs. in lakhs)
26.	M/s. Cyanamid (India) (Now M/s. Wyeth Ltd.)	Dimethyl Chloro-Tetracycline Hydrochloride etc.	4304.16/4274.72@
27	M/s. S.G. Pharmaceuticals (M/s. Ambalal Sarabhai Enterprises Ltd.)	Oxyphenbutazone	676.09
28.	M/s. John Wyeth and Geoffrey Manners (now Wyeth Ltd.)	Benzathine Pencillin G	1136.56
29.	M/s. Ethico Drugs & Chemicals Mfg. Co. Ltd.	Rifampicin	363.11

©There is difference of opinion among Members of DPLRC.

FDI in fertilizer sector

1824. SHRI T.T.V. DHINAKARAN: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) what is the foreign Director Investment (FDI) in the fertilizer sector so far;

(b) the reasons for the low FDI in this sector; and

(c) the steps taken to attract more investment?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI B.K. HANDIQUE): (a) The details of country-wise break-up of Foreign Direct Investment (FDI) proposals received during the period from 1.1.2000 to 30.4.2006 in the fertilizer sector are given in the statement (See below). The total inflow of FDI to the sector during this period has been Rs. 259.63 crores.

(b) and (c) The extent of FDI in this sector is dependent upon general investment climate in the country as well as overall policy framework regulating it from time to time.